At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 97 enrolled
Drug / intervention
Levofloxacin +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Investigation of the Efficacy of Antimycobacterial Therapy on Pulmonary Sarcoidosis Phase II Randomized, Double-blind, Placebo-controlled Trial
In Brief
A Phase 2 clinical trial evaluating Levofloxacin, Ethambutol, and 3 other interventions for Sarcoidosis; Antimycobacterial Therapy. Completed, enrolled 97 participants across 6 sites.
Detailed Summary
The primary purpose of this study is to investigate the efficacy and safety of oral antimycobacterial therapy in patients with confirmed progressive pulmonary sarcoidosis. We suspect that the CLEAR regimen will improve the absolute FVC percent predicted in chronic pulmonary sarcoidosis participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSarcoidosis; Antimycobacterial Therapy
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 2013
Enrollment StartMar 2014
Primary CompletionApr 2019
TodayJul 2026
First PostedDec 31, 2013
Enrollment StartMar 1, 2014
Primary CompletionApr 1, 2019
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 12.5 years ago
Interventions
Levofloxacindrug
Ethambutoldrug
Azithromycindrug
Rifampindrug
Placebodrug
This will serve as a placebo to the antibiotics used in antimycobacterial therapy.